ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” third-quarter ...

Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...

If you're holding shares of Vertex Pharmaceuticals or thinking about adding some to your portfolio, you're not alone in ...

Fintel reports that on October 10, 2025, Morgan Stanley maintained coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 18.17% Upside ...

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Vertex Pharmaceuticals (VRTX) shares saw mild movement today, with the stock ticking slightly higher over the past week.

Vertex Pharmaceuticals Inc. closed 22.25% short of its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Warren Buffett famously said that he and his investing managers "attempt to be fearful when others are greedy, and to be ...

Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...

As the industry loses one of its key female leaders in GSK CEO Emma Walmsley, BioSpace profiles the women leading the ...

After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top-20 pharma company. Still, there are many prominent women in pharma that ...